143 related articles for article (PubMed ID: 31965703)
1. Pharmacy hydroxyurea education materials for patients with sickle cell disease: An environmental scan and assessment of accuracy.
Cervi A; Diamantouros A; Azzam M; Lane SJ; Sapru H; Verhovsek M
Pediatr Blood Cancer; 2020 May; 67(5):e28179. PubMed ID: 31965703
[TBL] [Abstract][Full Text] [Related]
2. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
[TBL] [Abstract][Full Text] [Related]
3. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.
Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385
[No Abstract] [Full Text] [Related]
4. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
5. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
[TBL] [Abstract][Full Text] [Related]
6. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
Green NS; Manwani D; Matos S; Hicks A; Soto L; Castillo Y; Ireland K; Stennett Y; Findley S; Jia H; Smaldone A
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643377
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
9. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.
Reddy PS; Cai SW; Barrera L; King K; Badawy SM
Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095
[TBL] [Abstract][Full Text] [Related]
10. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
[TBL] [Abstract][Full Text] [Related]
11. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
[TBL] [Abstract][Full Text] [Related]
14. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.
Jabour SM; Beachy S; Coburn S; Lanzkron S; Eakin MN
J Racial Ethn Health Disparities; 2019 Dec; 6(6):1233-1243. PubMed ID: 31410784
[TBL] [Abstract][Full Text] [Related]
15. Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center.
Han J; Bhat S; Gowhari M; Gordeuk VR; Saraf SL
Pharmacotherapy; 2016 Nov; 36(11):1166-1172. PubMed ID: 27639254
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence.
Smith WR; McClish DK; Lottenberg R; Sisler IY; Sop D; Johnson S; Villella A; Liles D; Yang E; Chen I
Br J Haematol; 2022 Jan; 196(1):193-203. PubMed ID: 34786695
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review.
Yang M; Elmuti L; Badawy SM
Biomed Res Int; 2022; 2022():2122056. PubMed ID: 35898672
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
